BRF is a leading provider of comprehensive drug discovery services, committed to supporting the research and development needs of the pharmaceutical industry. With our advanced facilities, cutting-edge technologies, and expert scientific team, we offer a wide range of customized solutions to accelerate the discovery of novel therapeutics.

Our drug discovery services encompass the entire R&D process, starting from target identification and validation to lead optimization and preclinical development. We employ a multidisciplinary approach, combining bioinformatics, high-throughput screening, medicinal chemistry, and in vitro and in vivo pharmacology studies to drive the successful discovery of potential drug candidates.

In the initial stage of target identification and validation, we utilize state-of-the-art bioinformatics tools, molecular biology techniques, and disease pathway analysis to identify and validate relevant drug targets. This ensures that the selected targets are essential to the disease mechanism and hold promise for therapeutic intervention.

Moving forward, our high-throughput screening platforms enable rapid testing of large compound libraries against specific targets. This approach allows for the identification of potential hits that can be further optimized during the hit-to-lead optimization phase. Our team of experienced medicinal chemists leverages computational modeling and structure-activity relationship analysis to refine and enhance hit compounds, optimizing their potency, selectivity, and drug-like properties.

To assess the absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) properties of lead compounds, we conduct comprehensive in vitro and in vivo ADME-Tox profiling studies. These investigations provide valuable insights into the compound’s pharmacokinetics and safety profiles, helping in the selection of lead compounds for further development.

Our in vitro pharmacology studies play a vital role in evaluating the pharmacological activity and mechanism of action of lead compounds. Through a wide range of assays, including receptor binding, enzyme inhibition, and cell-based functional assays, we gather critical data on the interaction of compounds with biological targets, elucidating their pharmacological potential.

To further validate the efficacy of lead compounds, we offer diverse in vivo efficacy models, including disease models and xenograft models. These models provide valuable data on the therapeutic efficacy, dose response, and pharmacodynamics of potential drug candidates. Our experienced team designs and executes these studies with meticulous attention to detail and ethical standards.

Pharmacokinetic (PK) studies evaluate the compound’s absorption, distribution, metabolism, and excretion in animal models. These studies provide important information on bioavailability, half-life, and clearance, aiding in the optimization of dosing regimens and the prediction of human PK profiles.

Ensuring the safety and tolerability of potential drug candidates is of utmost importance. We conduct comprehensive safety assessment and toxicology studies, including acute toxicity, subchronic and chronic toxicity, genotoxicity, and reproductive and developmental toxicity assessments. These studies provide a thorough understanding of the compound’s safety profile.

Formulation development is another integral part of our drug discovery services. Our formulation experts collaborate with clients to develop suitable formulations for lead compounds, enhancing their stability, bioavailability, and patient compliance. This ensures effective delivery of potential drug candidates to the target site for optimal therapeutic outcomes.

At BRF, we prioritize scientific excellence, quality, and collaboration. Our services are aligned with industry standards and regulatory guidelines. With our focus on innovation, efficiency, and client-centricity, we strive to accelerate the discovery and development of transformative therapies that can improve patient lives and address unmet medical needs.